Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis

Journal of Clinical Psychiatry

Volumn 73, Issue 8, 2012, Pages 1128-1138

  Udina, Marc ^a,b   Castellví, Pere ^a   Moreno España, José ^a,b   Navinés, Ricard ^a   Valdés, Manuel ^a,b   Forns, Xavier ^c   Langohr, Klaus ^d   Solà, Ricard ^e   Vieta, Eduard ^a,b   Martín Santos, Rocío ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; INTERFERON; INTERLEUKIN 6; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ANTIVIRAL THERAPY; EDUCATIONAL STATUS; HEPATITIS C; HUMAN; MAJOR DEPRESSION; MEDICAL HISTORY; MENTAL DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW;

EID: 84865801719     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12r07694     Document Type: Review

References (71)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1-16. doi:10.105/s-20-9506 PubMed
2. Solà R, Cruz De Castro E, Hombrados M, et al. Prevalence of hepatitis B and hepatitis C viruses in different counties of Catalonia, Spain: cross-sectional study [in Spanish]. Med Clin (Barc). 2002;119(3):90-95. PubMed
3. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(suppl 2):61-80. doi:10.1/j.1478-3231.201.02540.x PubMed
4. Leone N, Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2005;51(1):31-46. PubMed
5. Schiff ER. Diagnosing and treating hepatitis C virus infection. Am J Manag Care. 2011;17(suppl 4):S108-S115. PubMed
6. Seeff LB, Hoofnagle JH. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis. 2003;7(1):261-287. doi:10.1016/S1089-3261(02)078-8 PubMed
7. Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35(5):1002- 1009. doi:10.1053/jhep.202.32672 PubMed
8. McHutchison JG, Gordon SC, Schiff ER, et al; Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339(21):1485-1492. doi:10.1056/NEJM19819392101 PubMed
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982. doi:10.1056/NEJMoa02047 PubMed
10. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965 PubMed.
11. Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol. 2009;44(10):1009-1015. doi:10.107/s0535-09-0126-7 PubMed
12. Poynard T, McHutchison J, Goodman Z, et al. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000;31(1):211-218. doi:10.102/hep.510310131 PubMed
13. Kwo PY, Lawitz EJ, McCone J, et al; SPRINT-1 Investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705-716. doi:10.1016/S0140-6736(10)60934-8 PubMed
14. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416. doi:10.1056/NEJMoa1012912 PubMed
15. Kraus MR, Schäfer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003;64(6):708-714. doi:10.408/JCP.v64n0614 PubMed
16. Dodd S, Malhi GS, Tiller J, et al. A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Aust N Z J Psychiatry. 2011;45(9):712-725. doi:10.3109/048674.201.595686 PubMed
17. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol. 2006;44(3):491-498. doi:10.1016/j.jhep.205.1.046 PubMed
18. Ademmer K, Beutel M, Bretzel R, et al. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics. 2001;42(4):365-367. doi:10.176/api.psy.42.4.365 PubMed
19. Martín-Santos R, Díez-Quevedo C, Castellví P, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha- 2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther. 2008;27(3):257-265. doi:10.1/j.1365-2036.207.03568.x PubMed
20. Horikawa N, Yamazaki T, Izumi N, et al. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry. 2003;25(1):34-38. doi:10.1016/S0163-8343(02)0239-6 PubMed
21. Malaguarnera M, Laurino A, Di Fazio I, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res. 2001;21(5):273-278. doi:10.1089/1079013017457 PubMed
22. Wichers MC, Koek GH, Robaeys G, et al. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med. 2005;35(3):433-441. doi:10.1017/S0329170403526 PubMed
23. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci. 2009;34(1):4-20. PubMed
24. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. 2001;15(1):7-24. PubMed
25. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):201-217. doi:10.1016/j.pnpbp. 204.1.03 PubMed
26. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24-31. doi:10.1016/j.it.205.1.06 PubMed
27. Smith AK, Simon JS, Gustafson EL, et al. Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C [published online ahead of print June 21, 2011]. Mol Psychiatry. doi:10.1038/mp.201.67 PubMed
28. Neri S, Bertino G, Petralia A, et al. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. J Clin Gastroenterol. 2010;44(9):e210-e217. PubMed
29. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1163-1174. doi:10.1/j.1365- 2036.207.0316.x PubMed
30. Amodio P, De Toni EN, Cavalletto L, et al. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J Affect Disord. 2005;84(1):93-98. doi:10.1016/j.jad.204.09.04 PubMed
31. Schäfer A, Wittchen H-U, Seufert J, et al. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C: a critical review. Int J Methods Psychiatr Res. 2007;16(4):186-201. doi:10.102/mpr.29 PubMed
32. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008- 2012. doi:10.101/jama.283.15.208 PubMed
33. Koepsell TD, Weiss NS. Epidemiologic Methods: Studying the Occurrence of Illness. New York, NY: Oxford University Press; 2003.
34. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Updated July 1, 2010. Accessed June 15, 2011.
35. Vandenbroucke JP, von Elm E, Altman DG, et al; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4(10):e297. doi:10.1371/journal. pmed.040297 PubMed
36. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)9046-2 PubMed
37. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
38. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. doi:10.136/bmj.315.7109.629 PubMed
39. Schwarzer G. Meta-Analysis With R, Version 1.6-1. http://cran.r-project. org. Updated 2010. Accessed July 20, 2011.
40. Miyaoka H, Otsubo T, Kamijima K, et al. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry. 1999;156(7):1120. PubMed
41. Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72(3):237-241. doi:10.1016/S0165-0327(02)0264-1 PubMed
42. Castéra L, Zigante F, Bastie A, et al. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology. 2002;35(4):978-979. doi:10.1053/jhep.202.32104 PubMed
43. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942-947. doi:10.1038/sj.mp.4019 PubMed
44. Kraus MR, Schäfer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002;16(6):1091-1099. doi:10.1046/j.1365-2036.202.01265.x PubMed
45. Russo S, Kema IP, Haagsma EB, et al. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Med. 2005;67(5):773-777. doi:10.1097/01.psy.017193.2804.d8 PubMed
46. Castéra L, Constant A, Henry C, et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2006;24(8):1223-1230. doi:10.1/j.1365-2036.206.03107.x PubMed
47. Dell'Osso L, Pini S, Maggi L, et al. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. J Psychosom Res. 2007;62(3):349-355. doi:10.1016/j.jpsychores.206.10.024 PubMed
48. Lotrich FE, Rabinovitz M, Gironda P, et al. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res. 2007;63(2):131-135. doi:10.1016/j.jpsychores.207.05.013 PubMed
49. Quarantini LC, Bressan RA, Galvão A, et al. Incidence of psychiatric side effects during pegylated interferon-α retreatment in nonresponder hepatitis C virus-infected patients. Liver Int. 2007;27(8):1098-1102. doi:10.1/j.1478-3231.207.01532.x PubMed
50. Robaeys G, De Bie J, Wichers MC, et al. Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha- 2b treatment by assessment of vegetative-depressive symptoms after four weeks. World J Gastroenterol. 2007;13(43):5736-5740. PubMed
51. Schäfer A, Scheurlen M, Weissbrich B, et al. Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression? Chemotherapy. 2007;53(4):292-299. doi:10.159/0102584 PubMed
52. Fontana RJ, Kronfol Z, Lindsay KL, et al; HALT-C Trial Group. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol. 2008;103(11):2766-2775. doi:10.1/j.1572-0241.208.02106.x PubMed
53. Pawelczyk T, Pawelczyk A, Strzelecki D, et al. Pegylated interferon α and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. Gen Hosp Psychiatry. 2008;30(6):501-508. doi:10.1016/j.genhospsych.208.03.01 PubMed
54. Castellví P, Navinés R, Gutierrez F, et al. Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality. J Clin Psychiatry. 2009;70(6):817-828. doi:10.408/JCP.08m04230 PubMed
55. Prather AA, Rabinovitz M, Pollock BG, et al. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun. 2009;23(8):1109-1116. doi:10.1016/j.bi.209.07.01 PubMed
56. Franzen PL, Buysse DJ, Rabinovitz M, et al. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res. 2010;177(1-2):240-245. doi:10.1016/j.psychres.209.02.01 PubMed
57. Raison CL, Borisov AS, Woolwine BJ, et al. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry. 2010;15(5):535-547. doi:10.1038/mp.208.58 PubMed
58. Su K-P, Huang S-Y, Peng C-Y, et al. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry. 2010;67(6):550-557. doi:10.1016/j.biopsych.209.1.05 PubMed
59. Wichers MC, Kenis G, Leue C, et al. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry. 2006;60(1):77-79. doi:10.1016/j.biopsych.205.1.024 PubMed
60. Lotrich FE, Ferrell RE, Rabinovitz M, et al. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry. 2009;65(4):344-348. doi:10.1016/j.biopsych.208. 08.09 PubMed
61. Lotrich FE, Ferrell RE, Rabinovitz M, et al. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol. 2010;33(4):191-197. doi:10.1097/WNF. 0b013e3181de896 PubMed
62. Lotrich FE, Loftis JM, Ferrell RE, et al. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy [published online ahead of print December 6, 2010]. J Interferon Cytokine Res. PubMed
63. Parker G, Brotchie H. Gender differences in depression. Int Rev Psychiatry. 2010;22(5):429-436. doi:10.3109/09540261.2010.492391 PubMed
64. Tse WS, Rochelle TL, Cheung JC. The relationship between personality, social functioning, and depression: a structural equation modeling analysis. Int J Psychol. 2011;46(3):234-240. doi:10.1080/0207594.201.5453 PubMed
65. Casey JE, Joyce PR. Personality disorder and the Temperament and Character Inventory in the elderly. Acta Psychiatr Scand. 1999;100(4):302-308. doi:10.1/j.160-047.19.tb10865.x PubMed
66. Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439-1445. doi:10.176/api.ps.60.1.1439 PubMed
67. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457. doi:10.1016/j. biopsych.209.09.03 PubMed
68. Diez-Quevedo C, Masnou H, Planas R, et al. Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(4):522-528. doi:10.408/JCP.09m05282blu PubMed
69. Uchida M, Hamada A, Yamasaki M, et al. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Drug Metab Pharmacokinet. 2004;19(6):438-443. doi:10.213/dmpk.19.438 PubMed
70. Marcellin P, Lau GKK, Zeuzem S, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int. 2008;28(4):477-485. doi:10.1/j.1478-3231.208.01696.x PubMed
71. Pierucci-Lagha A, Covault J, Bonkovsky HL, et al; HALT-C Trial Group. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics. 2010;51(2):137-148. PubMed